Key statistics dashboard for Incannex Healthcare Limited (IXHL). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA).
Stock Data
| Price | $3.64 |
| Market Cap | $44M |
| Enterprise Value | -$25.2M |
| Beta | 2.73 |
| Exchange | NASDAQ |
| Country | AU |
Valuation Multiples
| P/E Ratio | -2.82 |
| Price / Book | 0.58 |
| P/S | 653.76 |
| EV/EBITDA | 0.55 |
| EV/Sales | -378.08 |
| EV/FCF | 2.46 |
| P/FCF | -4.25 |
| Earnings Yield | -99.27% |
| FCF Yield | -23.51% |
Profitability
| Gross Margin | -192.70% |
| EBIT Margin | -68473.23% |
| EBITDA Margin | -68320.92% |
| Operating Margin | -38700.91% |
| Net Margin | -63187.52% |
| Return on Equity | -96.99% |
| Return on Assets | -56.12% |
| Return on Invested Capital | -35.04% |
| Return on Capital Employed | -35.10% |
Financial Health
| Current Ratio | 48.27 |
| Quick Ratio | 48.27 |
| Cash Ratio | 44.54 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.22% |
| Net Debt / EBITDA | 1.51 |
| Interest Coverage | -195.31 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -13.23 |
Per-Share Data
| Revenue per share | 0.01 |
| Book Value per share | 6.30 |
| Cash per share | 5.91 |
| FCF per share | -0.88 |
| Tangible Book Value per share | 6.30 |
| Dividend per share | 0.00 |
Related companies: AGEN · CGTX · IRD · LUCD · SCLX · SEER · STSS
Explore sector: Healthcare · Biotechnology
More sections of IXHL: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks